Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Period | PRIVIGEN IVIG | HIZENTRA SCIG | FLUAD adjuvanted | FLUCELVAX cell | FERINJECT / INJECTAFER |
|---|---|---|---|---|---|
| FY 2023 | 2,832 | 1,644 | 893 | 599 | 759 |
| FY 2024 | 3,624 | 1,961 | 1,040 | 535 | 759 |
| FY 2025 | 3,904 | 2,078 | 901 | 474 | 766 |
| FY 2026 | 4,017 | 2,167 | 968 | 503 | 653 |
The Australian government founds the Commonwealth Serum Laboratories in Melbourne. CSL is later privatized and listed (1994). Plasma is still the larger P&L; Seqirus is the vaccine arm.
CSL completes the purchase of Novartis's influenza vaccines business and launches the Seqirus brand. Flucelvax (cell) and Fluad (adjuvanted) sit here.
Seqirus FY Jun 2025: $2.166B total, Fluad $901M, Flucelvax $474M. Fiscal year is June, not calendar. Label the offset when comparing to Sanofi flu.